News
GenSight Biologics Announces Report Showing Visual Recovery After GS030 Optogenetic Treatment
News
GenSight Biologics Announces Report Showing Visual Recovery After GS030 Optogenetic Treatment

GenSight Biologics Announces Report Showing Visual Recovery After GS030 Optogenetic Treatment

February 02, 2022
Daniel Feldman
Gensight Biologics

GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced that the highly-regarded journal Nature Medicine has published the first case report of partial recovery of visual function in a blind patient with late-stage retinitis pigmentosa (RP). The subject is a participant in the ongoing PIONEER Phase I/II clinical trial of GenSight Biologics’ GS030 optogenetic therapy. Published in the May issue under the title “Partial recovery of visual function in a blind patient after optogenetic therapy”, the paper* is the first peer-reviewed documentation of visual recovery after a blind patient was treated with optogenetic therapy.

Currency: USD
USD - US Dollar
EUR - Euro
GBP - British Pound
CAD - Canada Dollars
AUD - Australia Dollars
JPY - Japan Yen
SEK - Sweden Kronor
NOK - Norway Kroner
IDR - Indonesia Rupiahs
BRL - Brazil Reais
RUB - Russia Rubles
THB - Thailand Baht
AED - Arab Emir. Dirham
Need Help?
Chat live with us
Request Quote
Want to call?

86-13799759387

WhatsApp
Track Order
Want to check the status of your order? You can put in your order number and click track order to find the tracking information or login your account to check the detail information.
order number
  • order number
  • tracking number